CMS determined the improper payment rate for immunosuppressive drugs was 15.7% in 2023, with a projected improper payment amount of $43.2 million. Organizations should review CMS' guidance on proper billing codes, coverage criteria, common denial reasons, and documentation requirements.
Our goal at HCPro is to provide revenue cycle professionals like you with the most up-to-date information on changes that affect your organization. After reviewing our product line, we decided to make changes to the Revenue Cycle Advisor. Starting in January 2025, HIM Briefings will have expanded, HIM-focused coverage and be available to Basic members, as we create an offer that focuses on Medicare regulations that affect your entire revenue cycle. For questions about your Revenue Cycle Advisor subscription/access level, please contact customer service at 800-650-6787.
Our goal at HCPro is to provide revenue cycle professionals like you with the most up-to-date information on changes that affect your organization. After reviewing our product line, we decided to make changes to the Revenue Cycle Advisor. The December 2024 issue of Briefings on HIPAA will be the last one as we sunset this publication to create an offer that focuses on Medicare regulations that affect your entire revenue cycle. For questions about your Revenue Cycle Advisor subscription, please contact customer service at 800-650-6787.
